Free serum IgE suppression with omalizumab and clinical outcomes in asthma

C. Liu (Chengdu, China), J. Li (Guangzhou, China), J. Yang (Beijing, China), L. Wang (Beijing, China), M. Humphries (Beijing, China), I. Ioannis Kottakis (Bazel, Switzerland), R. Fogel (East Hanover, United States of America), X. Lau (Petaling Jaya, Malaysia), N. Zhong (Guangzhou, China)

Source: International Congress 2019 – Clinical studies of asthma treatments
Session: Clinical studies of asthma treatments
Session type: Thematic Poster
Number: 2545
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Liu (Chengdu, China), J. Li (Guangzhou, China), J. Yang (Beijing, China), L. Wang (Beijing, China), M. Humphries (Beijing, China), I. Ioannis Kottakis (Bazel, Switzerland), R. Fogel (East Hanover, United States of America), X. Lau (Petaling Jaya, Malaysia), N. Zhong (Guangzhou, China). Free serum IgE suppression with omalizumab and clinical outcomes in asthma. 2545

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: